Anti-drug withdrawal syndrome composition and method of use
US4190660A · kind A · utility
2Cited by
2References
4Claims
0Family size
Inventor
Key dates
| Filing date | Aug 11, 1978 |
| Grant date | Feb 26, 1980 |
| Priority date | — |
| Expiry date | Aug 11, 1998 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/65583
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
A compound of the following formula ##STR1## wherein: X is H, OH, or halogen group; PA1 Y is OH, amino or halogen group; PA1 Z is OH, amino or halogen group; PA1 M is CH.sub.2 OH, CH.sub.2 PO.sub.4, CH.sub.2 Cl, CH.sub.2 Br, CH.sub.2 Fl, or CH.sub.2 1 group, and PA1 R is H.sub.2 or an alkyl group having 1 to 5 carbon atoms, when employed in pharmaceutically acceptable quantities alleviate the drug withdrawal syndrome from drug dependent warm blooded animals. A particular compound found suitable for this purpose is 1-(2-methyl-3-hydroxy-5-hydroxymethyl-4-pyridyl)-6,7-dihydroxy-1,2,3,4-tet rahydroisoquinoline.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.